Sovaldi
SOFOSBUVIR
- Strength
- 400 mg/1
- Form
- Tablet, Film Coated
- Class
- Hepatitis C Virus Nucleotide Analog NS5…
Gilead Sciences, Inc.
SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR
Listed by Gilead Sciences, Inc.
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
| Dosage form | Tablet, Film Coated |
|---|---|
| Route | Oral |
| Drug class | Hepatitis C Virus NS3/4A Protease Inhibitor; Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor |
| Approval route | NDA — original brand approval |
| NDC code | 61958-2401 |
| FDA application | NDA209195 |
| RxNorm concept | 1939329 |
| Package sizes listed | 1 |
| Marketed since | July 2017 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
SOFOSBUVIR
Gilead Sciences, Inc.
SOFOSBUVIR
Gilead Sciences, Inc.
SOFOSBUVIR
Gilead Sciences, Inc.
SOFOSBUVIR
Gilead Sciences, Inc.
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.